
What do the unlisted, Danish biotech companies Santaris Pharma, Ascendis Pharma, EpiTherapeutics, Forward Pharma, and Symphogen all have in common, aside from being among the most promising biotech companies in the country?
The answer is a high level of internationalization in their board rooms. The question is if more Danish biotech companies could go further, if they brought international board members on board, as it were, preferably early on in their development.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app